NCX 4251 did not meet the primary or secondary efficacy endpoints in a phase 2b clinical trial investigating the ophthalmic suspension in patients with acute exacerbations of blepharitis, according to a press release from Nicox.
However, NCX 4251 (fluticasone propionate ophthalmic suspension 0.1%) did show a signal of potential efficacy over placebo in the primary outcome measure of complete cure at day 15, the release said.
The primary outcome measure of the Mississippi trial was the proportion of patients achieving a complete cure in three signs and symptoms of blepharitis, including eyelid